Strategies for immunotherapy of cancer

Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1.
No abstract available

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neoplasm / therapeutic use
  • Antigen Presentation
  • Antigens, CD / physiology
  • Antigens, Neoplasm / immunology
  • Apoptosis
  • Cancer Vaccines / therapeutic use
  • Cytokines / genetics
  • Cytokines / physiology
  • Disease Susceptibility
  • Genetic Therapy
  • Humans
  • Immune Tolerance
  • Immunity, Innate
  • Immunoglobulin Idiotypes / immunology
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / immunology
  • Immunotherapy / methods*
  • Immunotherapy, Active
  • Immunotherapy, Adoptive
  • Lymphocyte Cooperation
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Mice
  • Neoplasm Proteins / immunology
  • Neoplasms / etiology
  • Neoplasms / immunology
  • Neoplasms / prevention & control
  • Neoplasms / therapy*
  • Neoplasms, Experimental / immunology
  • Neoplasms, Experimental / therapy
  • Oncogenic Viruses / immunology
  • Receptors, Tumor Necrosis Factor / physiology
  • T-Lymphocyte Subsets / immunology
  • Tumor Virus Infections / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Cytokines
  • Immunoglobulin Idiotypes
  • Neoplasm Proteins
  • Receptors, Tumor Necrosis Factor